Back

The long-term efficacy and safety of short dual antiplatelet therapy

28 August 2017 (14:45 - 15:00)
Organised by:
Congress Presentation Part of: Clinical Trial Update 1 PCI - Adjunctive drug therapy ESC Premium Access ESC Congress 2017

About the speaker

Photo
Professor Masato Nakamura

Toho University, Tokyo (Japan)

5 More presentations in this session

Presentation thumbnail
Increased all-cause mortality with intensive blood-pressure control in patients with a baseline systolic blood pressure of >=160 mmHg and a Lower Framingham risk score: a cautionary note from SPRINT
Professor T. Wang (Taipei, TW)
Slides Video
Presentation thumbnail
Systolic Blood Pressure Variability and Major Adverse Outcomes in Patients with Atrial Fibrillation: the AFFIRM Study
Associate Professor M. Proietti (Milan, IT)
Slides Video
Presentation thumbnail
Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial
Doctor R. Giugliano (Boston, US)
Slides Video
Presentation thumbnail
Mechanisms for the benefit of spironolactone in resistant hypertension in the PATHWAY-2 study
Professor B. Williams (London, GB)
Slides Video
Presentation thumbnail
Aldosterone Lethal Effects Blocked in Acute Myocardial Infarction Treated With or Without Reperfusion to Improve Outcome and Survival at Six Months Follow-up
Professor F. Beygui (Caen, FR)
Slides Video

Access the full session

Session thumbnail
Clinical Trial Update 1

The Event

Event poster

ESC Congress 2017

28 August 2017 14:45 CET
You may be interested in
thumbnail
Congress Presentation
Comparison of clinical outcomes with short-term and long-term DAPT after PCI using second-generation drug-eluting stents in high bleeding risk patient : a systematic review and meta-analysis
25 August 2023
thumbnail
Webinar
Antithrombotic treatment for dual pathway inhibition in cardiovascular disease patients
19 July 2023
thumbnail
Congress Presentation
Optimizing antiplatelet therapy in ACS: a network meta-analysis of simplified regimens
1 September 2025
thumbnail
Congress Presentation
Thirty-days versus standard duration of dual antiplatelet treatment after percutaneous coronary interventions: a systematic review and meta-analysis
27 August 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources